883231-23-0 Usage
General Description
Tert-Butyl (5-bromopyrimidin-2-yl)carbamate is a chemical compound with the molecular formula C10H14BrN3O2. It is a carbamate derivative used in the synthesis of pharmaceutical compounds and as a building block in organic chemistry. The tert-butyl group provides steric hindrance, making it useful in protecting functional groups during chemical reactions. The 5-bromopyrimidin-2-yl group, on the other hand, confers biological activity and is often incorporated into drug molecules. tert-Butyl (5-bromopyrimidin-2-yl)carbamate has potential applications in medicinal chemistry and drug discovery due to its structural versatility and functional groups. It is important to handle and use this compound with appropriate safety precautions and in accordance with established protocols for handling hazardous chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 883231-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,2,3 and 1 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 883231-23:
(8*8)+(7*8)+(6*3)+(5*2)+(4*3)+(3*1)+(2*2)+(1*3)=170
170 % 10 = 0
So 883231-23-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H12BrN3O2/c1-9(2,3)15-8(14)13-7-11-4-6(10)5-12-7/h4-5H,1-3H3,(H,11,12,13,14)
883231-23-0Relevant articles and documents
Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents
Peng, Wei,Tu, Zheng-Chao,Long, Zi-Jie,Liu, Quentin,Lu, Gui
, p. 644 - 654 (2015/12/31)
In this study, a series of novel 7 or 8-substituted 4-morpholine-quinazoline derivatives was designed and synthesized. Their PI3Kα inhibitory activities, antiproliferative activities against seven cancer cell lines, namely, PC-3, DU145, MCF-7, BT474, SK-BR-3, U937 and A431, were evaluated in vitro. Compound 17f proved to be a potential drug candidate with high PI3Kα inhibition activity (IC50 = 4.2 nM) and good antiproliferative activity. Compound 17f was also tested for its inhibitory activities against other kinases, such as PI3Kβ, PI3Kγ, PI3Kδ and mTOR, its effects on p-Akt (S473) and cell cycle. These results suggested that compound 17f could significantly inhibit the PI3K/Akt/mTOR pathway as a potent PI3K inhibitor and anticancer agent.
